Welcome to our dedicated page for Medifast SEC filings (Ticker: MED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medifast, Inc. (NYSE: MED) SEC filings page provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. These documents offer detailed insight into how Medifast reports its financial condition, governance decisions, compensation plans, and key strategic developments related to its health and wellness and metabolic health business.
Among the most important filings for MED are annual reports on Form 10-K and quarterly reports on Form 10-Q, which contain audited or reviewed financial statements, management’s discussion and analysis, and descriptions of risk factors relevant to Medifast’s coach-guided lifestyle system and metabolic health focus. Investors use these reports to understand revenue trends, margins, balance sheet strength, and the role of the OPTAVIA coach network in the company’s operations.
Medifast also files current reports on Form 8-K to disclose material events. Recent 8-K filings have addressed topics such as executive leadership transitions, changes in key officer roles, amendments to the company’s share incentive plan, and the release of quarterly earnings. These filings provide timely detail on matters like CEO succession planning, executive compensation arrangements, and shareholder votes on equity plans.
On this page, users can also review filings related to equity compensation and corporate governance, including documents that describe the Amended and Restated 2012 Share Incentive Plan and shareholder approval of additional share authorizations. Together, these materials help clarify how Medifast aligns incentives for executives, directors, and other participants in its equity programs.
Stock Titan enhances these filings with AI-powered summaries that explain complex sections in plain language, highlight key changes from prior periods, and surface notable items such as leadership changes or plan amendments. Real-time updates from EDGAR, combined with easy access to forms like 10-K, 10-Q, and 8-K, allow investors and researchers to follow Medifast’s regulatory disclosures and governance developments efficiently.
Medifast, Inc. outlines in its annual report a major strategic shift from traditional weight loss toward holistic metabolic health, built around science-backed products and a coach-guided lifestyle system. The company is launching new programs, including Metabolic Synchronization™, OPTAVIA ASCEND and GLP‑1 Nutrition Support Plans, and plans additional product innovations in 2026.
The model depends on independent coaches and a direct-to-consumer structure, but active earning coaches fell to 16,100 for the quarter ended December 31, 2025, from 27,100 a year earlier, a key headwind. Medifast highlights significant competition from GLP‑1 weight loss medications, macroeconomic pressures on consumers, and evolving FTC and direct‑selling regulations as material risks to growth and its strategic transformation.
Medifast, Inc. reported a sharp downturn in results for the fourth quarter and full year 2025 as its coach-guided weight-management model faced pressure from the rapid adoption of GLP-1 weight-loss drugs. Fourth quarter 2025 revenue fell 36.9% to $75.1 million, driven mainly by a 40.6% drop in independent active earning coaches to 16,100. Coach productivity improved, with revenue per active earning coach rising 6.2% to $4,664.
The company posted a fourth quarter net loss of $18.1 million, or $1.65 per diluted share, and a full year 2025 net loss of $18.7 million, or $1.70 per diluted share, including a $12.1 million non-cash valuation allowance on deferred tax assets. Gross margin compressed to 69.4% as fixed costs weighed on profitability despite lower selling, general and administrative expenses. Management emphasized a shift to a metabolic health-focused strategy and reinstated guidance.
For 2026, Medifast expects first quarter revenue of $65 million to $80 million and a loss per share of $0.15 to $0.70. Full year 2026 revenue is projected between $270 million and $300 million with a loss per share between $1.55 and $2.75. The company ended 2025 with $167.3 million in cash, cash equivalents and investment securities, no debt, and total stockholders’ equity of $198.9 million.
Medifast, Inc. received an amended Schedule 13G filing showing that three affiliated Susquehanna entities collectively report beneficial ownership of 148,944 shares of Medifast common stock, representing 1.4% of the outstanding shares as of the event date.
The reporting persons are G1 Execution Services, LLC, Susquehanna Fundamental Investments, LLC, and Susquehanna Securities, LLC. Susquehanna Securities, LLC’s position includes options to buy 139,300 shares. Medifast had 10,991,273 shares outstanding as of October 27, 2025, based on the company’s Form 10-Q.
The group certifies that the securities were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Medifast, indicating a passive investment stance under the Schedule 13G framework.
Charles Schwab Investment Management Inc. has filed an amended Schedule 13G reporting beneficial ownership of 776,829 shares of Medifast Inc. common stock, representing 7.06% of the outstanding class as of 12/31/2025. Schwab has sole voting and sole dispositive power over these shares.
The shares are held in the ordinary course of business and not with the purpose or effect of changing or influencing control of Medifast. Schwab acts as investment adviser to the Schwab Fundamental U.S. Small Company ETF, which on its own holds 5.12% of Medifast’s common stock.
Medifast, Inc. reported several leadership and compensation changes. Anthony Tyree, Chief Business Operations Officer and a named executive officer, will leave the company effective December 31, 2025. Under a separation agreement and the executive severance policy, he will receive a lump-sum payment equal to one year of salary of $415,873 plus a target bonus of $291,111, his 2025 bonus based on actual performance, prorated vesting of restricted and performance share units through December 31, 2025, continued welfare plan coverage at active employee rates through December 31, 2026 if he elects COBRA, and up to six months of outplacement assistance.
Effective January 5, 2026, Nicholas Johnson is promoted from Chief Field Operations Officer to President of Medifast, adding responsibility for enterprise marketing, scientific and clinical affairs, product development, and consumable product and plan management. On the same date, CEO and Chairman Daniel Chard announced a planned transition to non-executive Chairman effective June 1, 2026. His letter agreement reduces his annual salary from $1,000,000 to $800,000, target bonus from 115% to 100%, and target long-term incentive from $4,600,000 to $2,400,000, with prorated 2026 incentives and continued vesting of existing equity while serving as non-executive Chairman.
Medifast (MED): G1 Execution Services, Susquehanna Fundamental Investments, and Susquehanna Securities filed an amended Schedule 13G reporting beneficial ownership of 654,945 shares of common stock, equal to 6.0% of the class as of 09/30/2025.
The filing notes that Susquehanna Securities’ reported holdings include options to buy 613,400 shares. The reporting persons indicate shared voting and dispositive power over 654,945 shares, with certain sole powers listed individually on their cover pages. Medifast had 10,991,064 shares outstanding as of July 28, 2025, per the company’s Form 10‑Q.
The group certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Charles Schwab Investment Management, Inc. filed a Schedule 13G disclosing a passive stake in Medifast, Inc.
The filing reports 595,211 shares of common stock, representing 5.41% of the class, tied to the event date 09/30/2025. The firm holds sole voting power over 595,211 shares and sole dispositive power over 595,211 shares, with no shared voting or dispositive power.
The reporting person is classified as an investment adviser (IA) and certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Medifast (MED) reported a weak quarter as demand softened. Revenue was $89.4 million, down 36.2% year over year, and the company posted a net loss of $2.3 million ($0.21 per diluted share) versus a profit a year ago. Nine‑month revenue was $310.7 million, down 35.7%, with a net loss of $0.6 million.
Results reflect a sharp decline in the OPTAVIA coach network and productivity. Active earning coaches fell to 19,500 from 30,000, and average revenue per active coach slipped to $4,585. Gross margin narrowed to 69.5% (down 590 bps), pressured by lower volume leverage and a reserve tied to reformulating the Essential product line. SG&A fell in dollars but remained elevated at 74.1% of revenue.
Liquidity remains solid: cash, cash equivalents and investments were $173.5 million, with working capital of $161.1 million. Operating cash flow was $12.1 million for the nine months. The company exited its LifeMD equity position earlier in the year, contributing to $7.2 million of other income year‑to‑date. Shares outstanding were 10,991,273 as of October 27, 2025.
Medifast, Inc. (MED) reported an administrative update via Form 8-K. The company announced it issued a press release covering earnings for the third quarter ended September 30, 2025. The release is provided as Exhibit 99.1.
The disclosure under Item 2.02 is being furnished, not filed, meaning it is not subject to Section 18 of the Exchange Act and will not be incorporated into other filings unless specifically referenced. No financial figures are included in this notice; detailed results are contained in the attached press release.
Medifast Schedule 13G filing summary The reporting entities—G1 Execution Services, LLC; Susquehanna Fundamental Investments, LLC; and Susquehanna Securities, LLC—report aggregate beneficial ownership of 785,606 shares, representing 7.2% of Medifast's outstanding common stock based on 10,938,000 shares outstanding as of June 30, 2025. The filing expressly states that the Susquehanna Securities total includes options to acquire 695,200 shares.
The filing includes a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control. The report is executed and signed on August 13, 2025. No additional transactions, plans, or intentions are disclosed in this statement.